Serum Institute of India (SII), world’s largest vaccine manufacturer, has decided to pause clinical trials of Oxford-AstraZeneca or Covishield vaccine in India. “We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” SII has said in an official statement. “We are following DCGI’s instructions and will not be able to comment further on trials,” the statement added.
Global pharma major AstraZeneca had, late on Tuesday evening, announced that it was putting a halt on ongoing clinical trials for a coronavirus vaccine it was developing in collaboration with Oxford University after a volunteer developed neurological symptoms.
The Covid-19 tally in India rose to 4,465,863 after nearly 96,000 fresh cases were registered in a single day. The death toll also increased from 73,890 to 75,063, according to latest data released by the Ministry of Health and Family Welfare. The number of recoveries stood at 3,471,783.
Just a few days ago, India became the second country with the largest caseload, after the United States, which has over 6.3 million cases. India is followed by Brazil, Russia and Peru. However, in terms of deaths due to Covid-19, India ranks third after the US and Brazil. There are over 27.7 million cases of Covid-19 across the world, and 902,468 deaths, according to a Reuters tally.